LPCN
Price:
$6.09
Market Cap:
$32.57M
Lipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of neuroendocrine and metabolic disorders. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Its lead product candidate is TLANDO, an oral testosterone replacement therapy. The company's pipeline candidates also include LPCN 1144, an oral prodrug of bioidentical testosterone that has completed Phase II clinical trial for the treatment of non-cirrhotic non-alcoholic steatohepatitis; LPCN 1111, an oral prodrug of testosterone tridecanoate for once daily dosing, which has completed Phase II clinical trial ...[Read more]
Industry
Biotechnology
IPO Date
2013-10-22
Stock Exchange
NASDAQ
Ticker
LPCN
According to Lipocine Inc.’s latest financial reports and current stock price. The company's current ROE is -38.58%. This represents a change of 280.15% compared to the average of -10.15% of the last 4 quarters.
The mean historical ROE of Lipocine Inc. over the last ten years is -88.31%. The current -38.58% ROE has changed -56.32% with respect to the historical average. Over the past ten years (40 quarters), LPCN's ROE was at its highest in in the December 2021 quarter at 27.70%. The ROE was at its lowest in in the March 2020 quarter at -88.06%.
Average
-88.31%
Median
-78.78%
Minimum
-206.87%
Maximum
-1.39%
Discovering the peaks and valleys of Lipocine Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 2.07%
Maximum Annual ROE = -1.39%
Minimum Annual Increase = -98.98%
Minimum Annual ROE = -206.87%
Year | ROE | Change |
---|---|---|
2023 | -80.28% | 165.90% |
2022 | -30.19% | 2.07% |
2021 | -1.39% | -98.98% |
2020 | -136.65% | -33.94% |
2019 | -206.87% | 67.37% |
2018 | -123.60% | 11.80% |
2017 | -110.55% | 51.61% |
2016 | -72.92% | 68.14% |
2015 | -43.37% | -43.89% |
2014 | -77.29% | 227.12% |
The current ROE of Lipocine Inc. (LPCN) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-37.29%
5-year avg
-91.08%
10-year avg
-88.31%
Lipocine Inc.’s ROE is greater than Sigilon Therapeutics, Inc. (-81.98%), less than Reviva Pharmaceuticals Holdings, Inc. (664.92%), greater than ZyVersa Therapeutics, Inc. (-172.51%), less than Kiromic BioPharma, Inc. (337.72%), less than Unicycive Therapeutics, Inc. (294.74%), less than Checkpoint Therapeutics, Inc. (292.43%), less than Mustang Bio, Inc. (1.40%), greater than Fortress Biotech, Inc. (-226.63%), greater than Kodiak Sciences Inc. (-77.23%), greater than Ardelyx, Inc. (-46.60%), greater than Zura Bio Limited (-35.45%), greater than Hepion Pharmaceuticals, Inc. (-328.66%), less than AVROBIO, Inc. (29.68%), greater than Verastem, Inc. (-133.02%), less than Reviva Pharmaceuticals Holdings, Inc. (0%), less than Eyenovia, Inc. (664.92%), greater than Cognition Therapeutics, Inc. (-615.55%), greater than TransCode Therapeutics, Inc. (-118.11%), greater than null (-597.47%),
Company | ROE | Market cap |
---|---|---|
-81.98% | $56.22M | |
664.92% | $33.39M | |
-172.51% | $1.96M | |
337.72% | $1.73M | |
294.74% | $45.28M | |
292.43% | $154.67M | |
1.40% | $9.32M | |
-226.63% | $49.59M | |
-77.23% | $205.20M | |
-46.60% | $1.40B | |
-35.45% | $278.69M | |
-328.66% | $3.68M | |
29.68% | $5.24M | |
-133.02% | $156.95M | |
0% | $36.43M | |
664.92% | $44.32M | |
-615.55% | $19.04M | |
-118.11% | $8.89M | |
-597.47% | $0 |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Lipocine Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Lipocine Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Lipocine Inc.'s ROE?
How is the ROE calculated for Lipocine Inc. (LPCN)?
What is the highest ROE for Lipocine Inc. (LPCN)?
What is the 3-year average ROE for Lipocine Inc. (LPCN)?
What is the 5-year average ROE for Lipocine Inc. (LPCN)?
How does the current ROE for Lipocine Inc. (LPCN) compare to its historical average?